FDA accepts Trimel's CompleoTRT for review

Trimel Pharmaceuticals Corp. (TSX:TRL) said FDA accepted for review an NDA for CompleoTRT to treat testosterone deficiency in men. The PDUFA date is Feb. 28, 2014. The product is a bioadhesive intrana...